Can Eptifibatide Rewrite the NSTEMI Story? (Eptifibatide vs. Standard Care for NSTEMI: A 5‐Year Analysis of Major Adverse Cardiovascular Events) Background Coronary artery disease (CAD) is a leading cause of death worldwide. Among acute coronary syndromes, non-ST-elevation myocardial infarction (NSTEMI) poses a higher long-term risk than ST-.....

Can #Eptifibatide change the game for #NSTEMI patients? Our 5-year study at Tehran Heart Center (n=5309) found no significant impact on MACE (17.2% vs. 15.6%) or survival (HR 0.97, p=0.901) post-PCI. Time for targeted trials in high-risk groups? onlinelibrary.wiley.com/doi/10.1002/...